With the upcoming start of the second phase 2 test, Dr C and the MGT team will have met all milestones and deliverables that they have set. This is on of the key differentiating factors between RXI and other BIO companies. As RXI continues down their defined path and meets their deliverables, more and more investors will start to take notice. The by product is the increase in negative shorts who will try and bash the stock. I take it as a sigh of prosperous times to come.
Lotta...I take it also as a sign of prosperous times to come too. You are also correct to state that the company's meeting the set milestones is one of the factors that differentiate RXI from other Bio's.
If memory serves me correctly, Dr. C said in one of his earlier discussions last year that the Keloid phase 2 test would provide the quickest results and if successful could be used as justification to fast track with the FDA. Does anyone have any insight they can ad or is my memory flawed?